List view / Grid view
10 June 2016 | By
New data show promising results for venetoclax in patients with chronic lymphocytic leukaemia who have relapsed or become refractory (R/R) to treatment...
31 May 2016 | By Victoria White, Digital Content Producer
Reputation Institute has announced that AbbVie, Sanofi and Novo Nordisk top the RepTrak ranking of the most reputable pharmaceutical companies in the UK...
12 May 2016 | By Victoria White, Digital Content Producer
Empliciti (elotuzumab) is approved for use with Revlimid (lenalidomide) and dexamethasone in patients who have received at least one prior therapy...
The National Institute for Health and Care Excellence (NICE) has recommended AbbVie’s Humira (adalimumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adult patients with an inadequate response to conventional systemic HS therapy.
18 April 2016 | By Victoria White, Digital Content Producer
With eight weeks of treatment, 97-98 percent of GT1-3 HCV infected patients without cirrhosis treated with ABT-493 and ABT-530 achieved sustained SVR12...
15 April 2016 | By Victoria White, Digital Content Producer
AbbVie has announced new real-world data for Viekirax and Exviera, showing 96% of GT1 HCV patients and 100% of GT4 patients achieved SVR12...
14 April 2016 | By Victoria White, Digital Content Producer
AbbVie announced high SVR sates with Viekirax + Exviera regardless of the presence of resistance-associated variants prior to treatment in GT1 chronic HCV patients...
12 April 2016 | By Victoria White, Digital Content Producer
Venclexta is the first FDA-approved treatment that targets the BCL-2 protein, which supports cancer cell growth and is overexpressed in many CLL patients...
11 March 2016 | By Victoria White
A Phase III study demonstrated that sarilumab was superior to adalimumab in improving signs and symptoms in patients with active RA...
7 March 2016 | By Victoria White
BI 655066 is an anti-IL-23 monoclonal biologic antibody being evaluated in psoriasis, Crohn’s disease, psoriatic arthritis and asthma...
26 February 2016 | By Victoria White
The CHMP opinion of the Type-II variation application for Viekirax + Exviera is supported by data from the Phase 3b TURQUOISE-III study...
29 January 2016 | By Victoria White
Empliciti (elotuzumab) is an immunostimulatory antibody that specifically targets Signaling Lymphocyte Activation Molecule Family member 7 (SLAMF7), a cell-surface glycoprotein...
28 January 2016 | By Victoria White
The designation is for venetoclax in combination with HMAs for the treatment of patients with untreated AML who are ineligible to receive standard induction therapy...
26 January 2016 | By Victoria White
NICE recommends the seven biological disease modifying drugs as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs...
20 January 2016 | By Victoria White
Venetoclax is an investigational small molecule designed to selectively bind and inhibit the BCL-2 protein, which plays an important role in a process called apoptosis...
